Zimbabwe has declined a significant US healthcare agreement valued at $367m (272 million pounds) over five years because of the United States' demand for sensitive biological samples.
This move was revealed following a government memo from December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesperson has since clarified that the US was seeking health data for scientific study and profit while was not willing to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued dialogue to find a deal suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This rejection comes after a comparable case in Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to these new health pacts, constituting over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research without any certainty that the end products would be accessible to our citizens if a future pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were upending structures already set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This framework is intended to guarantee that when a country provides its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation might be structured in a manner that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but urged that talks need to persist considering much of the nation's HIV programmes depended on foreign aid.
"Where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
The halted deal underscores the complex challenges between receiving vital foreign assistance and safeguarding a country's data in an increasingly interconnected world.